{"id":"W3152750473","doi":"10.1016/s1470-2045(21)00081-4","title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pharmacyclics; Novartis Pharma; EMD Serono; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Johnson and Johnson; Genentech; Eisai; SkylineDx; Array BioPharma; Ipsen; Syndax Pharmaceuticals; Pfizer; Incyte; Sun Pharma; Regeneron Pharmaceuticals; Sanofi; AstraZeneca; EUSA Pharma; Roche; Novartis; GlaxoSmithKline; Amgen; Qbiotics; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Clinical endpoint; Hazard ratio; Placebo; Internal medicine; Quality of life (healthcare); Population; Clinical trial; Adverse effect; Oncology; Melanoma; Randomized controlled trial; Surgery; Cancer; Confidence interval; Pathology; Immunotherapy; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001901111,0.001841024,0.003462596,0.0004609783,0.0004138935,0.001045603,0.0009370374,0.001820135,0.00575931],"category_scores_gemma":[0.001430102,0.0006730346,0.00238779,0.000401105,0.001233648,0.001216054,0.0004672701,0.003115768,0.001171402],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000829813,"about_ca_system_score_gemma":0.0008036922,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001242963,"about_ca_topic_score_gemma":0.002338985,"domain_scores_codex":[0.9993485,0.0003415475,0.00003855669,0.0001281516,0.0000388539,0.0001044102],"domain_scores_gemma":[0.9993668,0.0001961915,0.0001621255,0.00005064988,0.00003175261,0.0001924124],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9864454,0.002382156,0.0001817253,0.0004622309,0.0006051614,0.00001537796,0.00002511373,0.0001884518,0.001559772,0.00004434349,0.0003214015,0.007768951],"study_design_scores_gemma":[0.9597868,0.03816483,0.0009430017,0.00003055044,0.0003429947,0.00001328077,0.00001222816,0.0002078397,0.0001888774,0.00008584572,0.0002136888,0.000009976476],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849888,0.007903379,0.0007239895,0.0006701347,0.0007353367,0.002199112,0.0009274982,0.0001404077,0.001711429],"genre_scores_gemma":[0.9870706,0.003348442,0.001274442,0.001034944,0.0004379411,0.002421027,0.000862762,0.00002715793,0.003522675],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00575931,"threshold_uncertainty_score":0.01926678,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1698307409166575,"score_gpt":0.4317912640571682,"score_spread":0.2619605231405107,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}